2dbf638a-46c1-4ec8-b81d-d859c7dcf989
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.470
- TNFA_SIGNALING_VIA_NFKB+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- INTERFERON_GAMMA_RESPONSE+0.450
- E2F_TARGETS+0.440
- INFLAMMATORY_RESPONSE+0.440
- IL6_JAK_STAT3_SIGNALING+0.430
- G2M_CHECKPOINT+0.410
- INTERFERON_ALPHA_RESPONSE+0.410
- IL2_STAT5_SIGNALING+0.350
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.330
- FATTY_ACID_METABOLISM-0.320
- ADIPOGENESIS-0.290
- APICAL_SURFACE-0.270
- HEME_METABOLISM-0.180
- PEROXISOME-0.170
- ESTROGEN_RESPONSE_EARLY-0.160
- MYOGENESIS-0.150
- GLYCOLYSIS-0.140
- BILE_ACID_METABOLISM-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943028 | — | — | 0.857 |
| 2 | SRR29022833 | — | D | 0.854 |
| 3 | TCGA-OR-A5JB-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.852 |
| 4 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.851 |
| 5 | BS_WAXJY4XQ | high-grade glioma | — | 0.850 |
| 6 | s0112234 | — | — | 0.847 |
| 7 | 346fe4c0-2ea0-45b4-8863-b0f9e7756ad6 | — | — | 0.846 |
| 8 | X55db60cd.e752.41b4.aa3e.f68d676031f7 | — | cohortA1 | 0.845 |
| 9 | 6fdba671-fb71-438f-ad62-e3d515e0222d | — | — | 0.842 |
| 10 | SRR29022839 | — | A | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |